BRAIN+ A/S

Brain+ is developing Ayla, the world’s first scalable dementia care platform, to offer practical, human- centered and clinically proven software -based dementia therapy and care solutions. The Company’s vision is to enhance quality of life for people affected with dementia on a global scale. The first Ayla platform product, Ayla – your CST Assistant, is a healthtech solution to offer scaled and high-quality implementation and access to Cognitive Stimulation Therapy (CST), the world -wide most renowned non -pharmaceutical dementia therapy. A Danish version of Ayla – your CST Assistant was launched in Denmark in July 2024 and an English version in the UK in October 2024. The UK represents the currently most attractive market for Brain+’ dementia care solutions, and commercial presence and sales are being built, targeting both UK private care homes and public memory services under the National Health System (NHS).